IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published In The Journal Of Clinical Oncology

IDM Pharma, Inc. (Nasdaq: IDMI) announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled “Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children’s Oncology Group.

More: continued here

Filed under: Bones on February 7th, 2008